Riestra S, Rodriguez M, Delgado M, Suárez A, González N, de la Mata M, Diaz G, Miño-Fugarolas G, Rodrigo L
Hospital Valle del Nalón, Asturias, Spain.
J Clin Gastroenterol. 1998 Apr;26(3):200-3. doi: 10.1097/00004836-199804000-00010.
To discover whether tamoxifen is able to extend the survival of patients with advanced hepatocellular carcinoma, we included 80 patients with cirrhosis and advanced hepatocellular carcinoma in a multicenter, double-blind, placebo-controlled trial in order to analyze the influence of treatment with tamoxifen on survival. The patients were randomized to receive tamoxifen, 40 mg/day (group 1), or placebo (group 2). Both groups were similar in age, sex, etiology of cirrhosis, biochemical, hematologic and hormonal parameters, morphology of the tumor (nodular vs multinodular or massive), Child-Pugh's score, and Okuda's stage. The 1-year survival rate was similar in both groups (30% in group 1 vs 37.8% in group 2; p = 0.31). Tamoxifen treatment was well tolerated by the patients. We conclude that tamoxifen does not extend the survival of patients with cirrhosis and advanced hepatocellular carcinoma.
为了探究他莫昔芬是否能够延长晚期肝细胞癌患者的生存期，我们将80例肝硬化合并晚期肝细胞癌患者纳入一项多中心、双盲、安慰剂对照试验，以分析他莫昔芬治疗对生存期的影响。患者被随机分为两组，一组接受他莫昔芬治疗，每日40毫克（第1组），另一组接受安慰剂治疗（第2组）。两组患者在年龄、性别、肝硬化病因、生化、血液学和激素参数、肿瘤形态（结节状与多结节状或巨块型）、Child-Pugh评分以及奥田分期方面均相似。两组的1年生存率相似（第1组为30%，第2组为37.8%；p = 0.31）。患者对他莫昔芬治疗耐受性良好。我们得出结论，他莫昔芬不能延长肝硬化合并晚期肝细胞癌患者的生存期。
